{"id":8885,"date":"2025-12-18T09:00:00","date_gmt":"2025-12-18T07:00:00","guid":{"rendered":"https:\/\/www.msd.ch\/fr\/?post_type=news_item&#038;p=8885"},"modified":"2026-03-10T12:21:08","modified_gmt":"2026-03-10T10:21:08","slug":"nouvelle-prise-en-charge-pour-le-cancer-du-sein-et-du-poumon","status":"publish","type":"news_item","link":"https:\/\/www.msd.ch\/fr\/news\/nouvelle-prise-en-charge-pour-le-cancer-du-sein-et-du-poumon\/","title":{"rendered":"L\u2019Office f\u00e9d\u00e9ral de la sant\u00e9 publique inscrit le pembrolizumab pour deux nouvelles indications \u2013 de cancer du sein et de cancer du poumon \u2013 sur la Liste des sp\u00e9cialit\u00e9s pour le remboursement"},"content":{"rendered":"","protected":true},"excerpt":{"rendered":"","protected":true},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[30],"class_list":["post-8885","news_item","type-news_item","status-publish","post-password-required","hentry","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pembrolizumab: remboursement pour le TNBC et le CPNPC - msd.ch<\/title>\n<meta name=\"description\" content=\"L\u2019OFSP inscrit le pembrolizumab (KEYTRUDA\u00ae) pour le TNBC et le CPNPC sur la liste des sp\u00e9cialit\u00e9s remboursables.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/fr\/news\/nouvelle-prise-en-charge-pour-le-cancer-du-sein-et-du-poumon\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pembrolizumab: remboursement pour le TNBC et le CPNPC - msd.ch\" \/>\n<meta property=\"og:description\" content=\"L\u2019OFSP inscrit le pembrolizumab (KEYTRUDA\u00ae) pour le TNBC et le CPNPC sur la liste des sp\u00e9cialit\u00e9s remboursables.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/fr\/news\/nouvelle-prise-en-charge-pour-le-cancer-du-sein-et-du-poumon\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T10:21:08+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.msd.ch\/fr\/news\/nouvelle-prise-en-charge-pour-le-cancer-du-sein-et-du-poumon\/\",\"url\":\"https:\/\/www.msd.ch\/fr\/news\/nouvelle-prise-en-charge-pour-le-cancer-du-sein-et-du-poumon\/\",\"name\":\"Pembrolizumab: remboursement pour le TNBC et le CPNPC - msd.ch\",\"isPartOf\":{\"@id\":\"https:\/\/www.msd.ch\/fr\/#website\"},\"datePublished\":\"2025-12-18T07:00:00+00:00\",\"dateModified\":\"2026-03-10T10:21:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.msd.ch\/fr\/news\/nouvelle-prise-en-charge-pour-le-cancer-du-sein-et-du-poumon\/#breadcrumb\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.msd.ch\/fr\/#website\",\"url\":\"https:\/\/www.msd.ch\/fr\/\",\"name\":\"msd.ch\",\"description\":\"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s&#039;engagent dans ce sens.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.msd.ch\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pembrolizumab: remboursement pour le TNBC et le CPNPC - msd.ch","description":"L\u2019OFSP inscrit le pembrolizumab (KEYTRUDA\u00ae) pour le TNBC et le CPNPC sur la liste des sp\u00e9cialit\u00e9s remboursables.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/fr\/news\/nouvelle-prise-en-charge-pour-le-cancer-du-sein-et-du-poumon\/","og_locale":"en_US","og_type":"article","og_title":"Pembrolizumab: remboursement pour le TNBC et le CPNPC - msd.ch","og_description":"L\u2019OFSP inscrit le pembrolizumab (KEYTRUDA\u00ae) pour le TNBC et le CPNPC sur la liste des sp\u00e9cialit\u00e9s remboursables.","og_url":"https:\/\/www.msd.ch\/fr\/news\/nouvelle-prise-en-charge-pour-le-cancer-du-sein-et-du-poumon\/","og_site_name":"msd.ch","article_modified_time":"2026-03-10T10:21:08+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/fr\/news\/nouvelle-prise-en-charge-pour-le-cancer-du-sein-et-du-poumon\/","url":"https:\/\/www.msd.ch\/fr\/news\/nouvelle-prise-en-charge-pour-le-cancer-du-sein-et-du-poumon\/","name":"Pembrolizumab: remboursement pour le TNBC et le CPNPC - msd.ch","isPartOf":{"@id":"https:\/\/www.msd.ch\/fr\/#website"},"datePublished":"2025-12-18T07:00:00+00:00","dateModified":"2026-03-10T10:21:08+00:00","breadcrumb":{"@id":"https:\/\/www.msd.ch\/fr\/news\/nouvelle-prise-en-charge-pour-le-cancer-du-sein-et-du-poumon\/#breadcrumb"},"inLanguage":"en-US"},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/fr\/#website","url":"https:\/\/www.msd.ch\/fr\/","name":"msd.ch","description":"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s&#039;engagent dans ce sens.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item\/8885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":12,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item\/8885\/revisions"}],"predecessor-version":[{"id":9087,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item\/8885\/revisions\/9087"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/media?parent=8885"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/tags?post=8885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}